JP2020500866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500866A5 JP2020500866A5 JP2019529156A JP2019529156A JP2020500866A5 JP 2020500866 A5 JP2020500866 A5 JP 2020500866A5 JP 2019529156 A JP2019529156 A JP 2019529156A JP 2019529156 A JP2019529156 A JP 2019529156A JP 2020500866 A5 JP2020500866 A5 JP 2020500866A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- group
- pharmaceutical composition
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 108010002459 HIV Integrase Proteins 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- 229960004748 abacavir Drugs 0.000 claims 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 229960004525 lopinavir Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- -1 2 - cyclopropyl Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960003277 atazanavir Drugs 0.000 claims 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 1
- 229960005107 darunavir Drugs 0.000 claims 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims 1
- 229960002814 rilpivirine Drugs 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 0 CC*C1=C(*C(C)(C)N*2C(C)(*)*(*)C3=O)*2C3=C(*C)C1=O Chemical compound CC*C1=C(*C(C)(C)N*2C(C)(*)*(*)C3=O)*2C3=C(*C)C1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662429376P | 2016-12-02 | 2016-12-02 | |
| US62/429,376 | 2016-12-02 | ||
| PCT/US2017/064116 WO2018102634A1 (en) | 2016-12-02 | 2017-12-01 | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500866A JP2020500866A (ja) | 2020-01-16 |
| JP2020500866A5 true JP2020500866A5 (enExample) | 2021-01-14 |
Family
ID=62242756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529156A Ceased JP2020500866A (ja) | 2016-12-02 | 2017-12-01 | Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10934312B2 (enExample) |
| EP (1) | EP3548031B1 (enExample) |
| JP (1) | JP2020500866A (enExample) |
| KR (1) | KR20190086017A (enExample) |
| CN (1) | CN110062627A (enExample) |
| AU (1) | AU2017367714B2 (enExample) |
| BR (1) | BR112019011074B1 (enExample) |
| CA (1) | CA3042314A1 (enExample) |
| MX (1) | MX384729B (enExample) |
| RU (1) | RU2749043C2 (enExample) |
| WO (1) | WO2018102634A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230571A (es) | 2018-05-31 | 2024-01-22 | Shionogi & Co | DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644) |
| EP3805221A4 (en) | 2018-05-31 | 2022-01-05 | Shionogi & Co., Ltd | POLYCYCLIC PYRIDONE DERIVATIVE |
| WO2019236396A1 (en) | 2018-06-05 | 2019-12-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| CN113874079B (zh) | 2019-03-22 | 2024-11-08 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN112047945B (zh) * | 2020-09-10 | 2021-11-12 | 浙江大学 | 螺环吡啶酮衍生物及应用 |
| WO2022072520A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| DK4196479T5 (da) | 2021-01-19 | 2025-01-02 | Gilead Sciences Inc | Substituerede pyridotriazinforbindelser og anvendelser deraf |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| CA2463976C (en) | 2001-10-26 | 2007-02-13 | Benedetta Crescenzi | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| AU2003216049B2 (en) | 2002-01-17 | 2008-07-17 | Merck Sharp & Dohme Corp. | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors |
| IL164491A0 (en) | 2002-04-26 | 2005-12-18 | Gilead Sciences Inc | Non nucleoside reverse transcriptase inhibitors |
| ATE481401T1 (de) | 2002-12-27 | 2010-10-15 | Angeletti P Ist Richerche Bio | Tetrahydro-4h-pyridoä1,2-aüpyrimidine und verwandte verbindungen verwendbar als hiv integrase hemmer |
| US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| CN101146811B (zh) | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| PT3284520T (pt) | 2005-04-28 | 2019-09-10 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv |
| WO2007049675A1 (ja) * | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| KR20120087916A (ko) | 2009-10-13 | 2012-08-07 | 엘랑코 애니멀 헬쓰 아일랜드 리미티드 | 마크로시클릭 인테그라제 억제제 |
| US8716293B2 (en) | 2010-04-02 | 2014-05-06 | Janssen R&D Ireland | Macrocyclic integrase inhibitors |
| US9714243B2 (en) * | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| US9493479B2 (en) * | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
| PT2997033T (pt) | 2013-05-17 | 2018-01-25 | Merck Sharp & Dohme | Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase |
| WO2014200880A1 (en) * | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| WO2015089847A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
-
2017
- 2017-12-01 RU RU2019116590A patent/RU2749043C2/ru active
- 2017-12-01 EP EP17876015.3A patent/EP3548031B1/en active Active
- 2017-12-01 AU AU2017367714A patent/AU2017367714B2/en not_active Ceased
- 2017-12-01 WO PCT/US2017/064116 patent/WO2018102634A1/en not_active Ceased
- 2017-12-01 JP JP2019529156A patent/JP2020500866A/ja not_active Ceased
- 2017-12-01 CA CA3042314A patent/CA3042314A1/en not_active Abandoned
- 2017-12-01 US US16/465,614 patent/US10934312B2/en active Active
- 2017-12-01 KR KR1020197018596A patent/KR20190086017A/ko not_active Withdrawn
- 2017-12-01 CN CN201780074646.6A patent/CN110062627A/zh active Pending
- 2017-12-01 MX MX2019006449A patent/MX384729B/es unknown
- 2017-12-01 BR BR112019011074-7A patent/BR112019011074B1/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500866A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2737190C2 (ru) | Ингибиторы репликации вируса гриппа, способы их применения и использование | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| RU2019116590A (ru) | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| RU2018137389A (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
| JP2016530259A5 (enExample) | ||
| JP2015501845A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2018516963A5 (enExample) | ||
| JP2019518059A5 (enExample) | ||
| WO2017040993A4 (en) | Small molecule inhibitors of dyrk1a and uses thereof | |
| JP2015509983A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
| JP2019526596A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2017505314A5 (enExample) | ||
| JP2013528600A5 (enExample) | ||
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
| JP2017517565A5 (enExample) | ||
| JP2017522273A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения |